Aszimmetrikus dimetilarginin: a cardiovascularis                     betegségek prediktora?

Németh, Balázs; Kabos, Peter; Németh, Ádám; Lenkey, Zsófia; Cziráki, Attila; Kiss, István; Sulyok, E.; Ajtay, Zénó

doi:10.1556/650.2016.30396

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asymmetric dimethylarginine (ADMA) is another well-recognized marker of inflammation and oxidative stress 15,16. The major biological function of ADMA is the inhibition of nitric oxide synthase (NOS), which is responsible for generating nitric oxide (NO) from L-Arginine (L-Arg)17.…”

Section: Introductionmentioning

confidence: 99%

<p>Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?</p>

Németh¹,

Péter²,

Boncz³

et al. 2019

TCRM

Self Cite

View full text Add to dashboard Cite

Purpose Psoriasis is one of the most common lifelong lasting dermatologic diseases. According to the latest studies, psoriatic patients have a higher risk of developing cardiovascular diseases. Psoriasis is considered as a systemic inflammatory disease. Several oxidative stress markers have been shown to be elevated in psoriasis. However, a panel of biomarkers has not been used yet. This study was aimed at exploring the connection between a panel of biomarkers (C-reactive protein, asymmetric dimethylarginine, uric acid, total antioxidant capacity, malondialdehyde, and orosomucoid [ORM]) and cardiovascular risk in psoriatic patients. Patients and methods The inclusion criterion was the onset of psoriasis with skin lesions. Exclusion criteria were impaired renal function (eGFR<60 mL/min/1.73 m 2 ), acute inflammations (urinary, respiratory, skin inflammation, etc), autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, or inflammatory bowel disease), and any kind of biological antipsoriatic treatment. Patients with a medical history of myocardial infarction, coronary heart disease, stroke, transient ischemic attack, and carotid artery stenosis were also excluded. Biomarkers were measured by routine procedures, ELISA and HPLC. QRISK®2-2017 was used to assess 10-year risk of cardiovascular disease development. Psoriasis severity was measured by the Psoriasis Area and Severity Index. Results One hundred and fourteen psoriatic patients were enrolled. Only urinary orosomucoid and urinary orosomucoid/urinary creatinine (u-ORM/u-CREAT) ratio showed significant correlation with QRISK score (u-ORM, r=0.245; u-ORM/u-CREAT, r=0.309). When comparing mild psoriatic patients to moderate psoriatic patients, significant differences could only be found in u-ORM and u-ORM/u-CREAT ratio. Conclusion There seems to be a connection between urinary ORM and cardiovascular risk. U-ORM and u-ORM/u-CREAT ratio could be used as an indicator of low-grade inflammation in mild and moderate psoriasis. However, it is the 10-year follow-up of cardiovascular events that will determine the usefulness of this biomarker panel.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?</p>

Németh¹,

Péter²,

Boncz³

et al. 2019

TCRM

Self Cite

View full text Add to dashboard Cite

show abstract

Angiotensin-converting Enzyme Inhibition Improves the Effectiveness of Transcutaneous Carbon Dioxide Treatment

Németh

Kiss

Jencsik³

et al. 2017

View full text Add to dashboard Cite

show abstract

Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges

Madir,

Grgurevic,

Tsochatzis

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

Portal hypertension (PH) has traditionally been observed as a consequence of significant fibrosis and cirrhosis in advanced non-alcoholic fatty liver disease (NAFLD). However, recent studies have provided evidence that PH may develop in earlier stages of NAFLD, suggesting that there are additional pathogenetic mechanisms at work in addition to liver fibrosis. The early development of PH in NAFLD is associated with hepatocellular lipid accumulation and ballooning, leading to the compression of liver sinusoids. External compression and intra-luminal obstacles cause mechanical forces such as strain, shear stress and elevated hydrostatic pressure that in turn activate mechanotransduction pathways, resulting in endothelial dysfunction and the development of fibrosis. The spatial distribution of histological and functional changes in the periportal and perisinusoidal areas of the liver lobule are considered responsible for the pre-sinusoidal component of PH in patients with NAFLD. Thus, current diagnostic methods such as hepatic venous pressure gradient (HVPG) measurement tend to underestimate portal pressure (PP) in NAFLD patients, who might decompensate below the HVPG threshold of 10 mmHg, which is traditionally considered the most relevant indicator of clinically significant portal hypertension (CSPH). This creates further challenges in finding a reliable diagnostic method to stratify the prognostic risk in this population of patients. In theory, the measurement of the portal pressure gradient guided by endoscopic ultrasound might overcome the limitations of HVPG measurement by avoiding the influence of the pre-sinusoidal component, but more investigations are needed to test its clinical utility for this indication. Liver and spleen stiffness measurement in combination with platelet count is currently the best-validated non-invasive approach for diagnosing CSPH and varices needing treatment. Lifestyle change remains the cornerstone of the treatment of PH in NAFLD, together with correcting the components of metabolic syndrome, using nonselective beta blockers, whereas emerging candidate drugs require more robust confirmation from clinical trials.

show abstract

Aszimmetrikus dimetilarginin: a cardiovascularis betegségek prediktora?

Cited by 3 publications

References 24 publications

<p>Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?</p>

<p>Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?</p>

Angiotensin-converting Enzyme Inhibition Improves the Effectiveness of Transcutaneous Carbon Dioxide Treatment

Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges

Contact Info

Product

Resources

About